Overview
Sickle cell-delta beta^0^-thalassemia is a severe hemoglobinopathy characterized by the co-inheritance of sickle cell disease (HbSS or HbS/β0-thalassemia) and the delta-beta^0^-thalassemia mutation, which further reduces the production of functional hemoglobin. This condition leads to chronic hemolytic anemia, vaso-occlusive crises, and organ damage due to the abnormal sickling of red blood cells under deoxygenated conditions. Primarily affecting individuals of African, Mediterranean, and Southeast Asian descent, the clinical burden is significant, often necessitating frequent medical interventions and monitoring. Understanding this condition is crucial for clinicians to manage acute complications effectively and improve long-term outcomes in affected patients 13.Pathophysiology
The pathophysiology of sickle cell-delta beta^0^-thalassemia stems from the combined effects of the sickle cell mutation and the delta-beta^0^-thalassemia mutation. The sickle cell mutation (HbS) results in the polymerization of hemoglobin under low oxygen tension, causing red blood cells to deform into a characteristic sickle shape. These sickled cells are prone to hemolysis and can obstruct small blood vessels, leading to vaso-occlusive crises and tissue infarction. The delta-beta^0^-thalassemia mutation further diminishes the production of normal adult hemoglobin (HbA), exacerbating the imbalance towards HbS and reducing the overall hemoglobin levels. This dual defect intensifies the severity of hemolytic anemia and increases the frequency and severity of clinical manifestations such as pain crises, acute chest syndrome, and organ dysfunction 3.Epidemiology
The exact incidence and prevalence of sickle cell-delta beta^0^-thalassemia are not well-documented separately from broader sickle cell disease categories due to its rarity and the complexity of genetic inheritance patterns. However, it predominantly affects populations with a high prevalence of sickle cell trait, such as those of African, Mediterranean, and Southeast Asian descent. Geographic regions with endemic malaria historically have higher carrier frequencies of sickle cell mutations, including delta-beta^0^-thalassemia. Over time, there has been a trend towards better identification and reporting of these rare genotypes through advanced genetic screening, though large-scale epidemiological studies remain limited 12.Clinical Presentation
Patients with sickle cell-delta beta^0^-thalassemia typically present with a spectrum of symptoms characteristic of severe sickle cell disease, often exacerbated by the additional impact of thalassemia. Common clinical features include:
Chronic Anemia: Persistent fatigue, pallor, and shortness of breath.
Vaso-occlusive Crises: Recurrent episodes of severe pain, often in bones, abdomen, or chest, indicative of acute chest syndrome or priapism.
Acute Chest Syndrome: Cough, fever, and difficulty breathing, mimicking pneumonia.
Splenic and Hepatic Dysfunction: Enlarged spleen, jaundice, and increased susceptibility to infections.
Organ Damage: Chronic complications affecting kidneys, brain, and other organs due to recurrent ischemia.
Red-flag features include unexplained fever, severe pain lasting more than a few hours, and signs of acute chest syndrome, necessitating prompt diagnostic evaluation and intervention 3.Diagnosis
The diagnosis of sickle cell-delta beta^0^-thalassemia involves a combination of clinical evaluation and laboratory testing:
Hemoglobin Electrophoresis: Confirms the presence of HbS and identifies the absence of delta-globin chain production.
Complete Blood Count (CBC): Reveals microcytic anemia, elevated reticulocyte count, and characteristic sickle cells on peripheral smear.
Genetic Testing: Confirms the specific mutations in the beta-globin gene and delta-globin gene.
Specific Criteria and Tests:
Hemoglobin Levels: Typically <9 g/dL 13.
Peripheral Blood Smear: Presence of sickle-shaped cells, target cells, and nucleated red blood cells.
Genetic Analysis: Identification of HbS mutation and delta-beta^0^-thalassemia deletion.
Differential Diagnosis:
- Thalassemia Major: Elevated HbA2 levels, absence of sickle cells on smear.
- Sickle Cell Trait: Normal hemoglobin levels, rare sickle cells on smear.
- Other Hemoglobinopathies: Specific genetic mutations and clinical features distinct from sickle cell-delta beta^0^-thalassemia 3.Management
Initial Management
Hydroxyurea: First-line therapy to increase fetal hemoglobin (HbF) production, reducing vaso-occlusive crises. Dose: 1-2 mg/kg/day 3.
Pain Management: Opioids for acute pain crises; non-steroidal anti-inflammatory drugs (NSAIDs) for milder pain.
Hydration and Oxygen: Maintain hydration and provide supplemental oxygen as needed.
Monitoring: Regular CBC, reticulocyte count, and clinical assessments for signs of complications.Second-Line Management
Blood Transfusions: Regular transfusions for severe anemia or stroke prevention. Indicated if hemoglobin <7 g/dL or significant organ dysfunction.
Iron Chelation: Deferoxamine or deferasirox for iron overload due to frequent transfusions.
Hydroxycarbamide (Hydroxyurea): Continued use if initial response is positive.
Monitoring: Regular ferritin levels, liver function tests, and echocardiograms.Refractory or Specialist Escalation
Stem Cell Transplantation: Considered for patients with severe complications unresponsive to conventional therapy. Requires HLA-matched donor.
Chronic Transfusion Therapy: Lifelong transfusions for secondary stroke prevention or severe anemia.
Supportive Care: Multidisciplinary approach including hematology, pulmonology, nephrology, and pain management specialists.
Contraindications: Absolute contraindications for stem cell transplantation include advanced age, comorbidities, and lack of suitable donor 3.Complications
Acute Complications
Vaso-occlusive Crises: Frequent episodes of severe pain, acute chest syndrome, and priapism.
Infections: Increased risk due to splenic dysfunction, particularly encapsulated organisms.
Chronic Complications
Organ Damage: Chronic kidney disease, avascular necrosis, and cognitive impairment.
Stroke: Particularly in children, necessitating regular transcranial Doppler screening.
Management Triggers: Prompt recognition and management of pain crises, regular vaccinations, and surveillance for silent strokes and organ dysfunction 3.Prognosis & Follow-up
The prognosis for patients with sickle cell-delta beta^0^-thalassemia is generally poor compared to other forms of sickle cell disease due to the compounded effects of both conditions. Prognostic indicators include frequency of vaso-occlusive crises, organ damage, and response to hydroxyurea. Recommended follow-up intervals include:
Monthly: CBC, reticulocyte count, pain assessments.
Quarterly: Liver function tests, ferritin levels, echocardiograms.
Annually: Comprehensive clinical evaluation, transcranial Doppler for stroke risk assessment.
Regular monitoring helps in early detection and management of complications, improving quality of life and longevity 3.Special Populations
Pediatrics
Early Diagnosis: Newborn screening programs are crucial for early identification.
Growth Monitoring: Regular assessments for growth retardation and nutritional support.
Stroke Prevention: Transcranial Doppler screening and prophylactic transfusions if indicated.
Elderly
Increased Comorbidities: Management requires consideration of age-related conditions like cardiovascular disease.
Medication Adjustments: Careful dosing of transfusions and iron chelation to avoid toxicity.
Pregnancy
Close Monitoring: Increased risk of preeclampsia, preterm labor, and fetal growth restriction.
Hemoglobin Management: Regular transfusions to maintain hemoglobin levels >9 g/dL.
Delivery Planning: Consultation with hematology and obstetric teams for optimal delivery strategy 3.Key Recommendations
Initiate Hydroxyurea: For patients with sickle cell-delta beta^0^-thalassemia to increase fetal hemoglobin production, dose 1-2 mg/kg/day (Evidence: Strong) 3.
Regular Hemoglobin Electrophoresis: Confirm diagnosis and monitor disease progression (Evidence: Strong) 13.
Screen for Vaso-occlusive Crises: Frequent monitoring for signs of pain crises and acute chest syndrome (Evidence: Moderate) 3.
Consider Transfusion Therapy: For severe anemia or stroke prevention, maintain hemoglobin levels >7 g/dL (Evidence: Moderate) 3.
Iron Chelation: Essential for patients requiring regular transfusions to prevent iron overload (Evidence: Strong) 3.
Multidisciplinary Care: Involvement of hematologists, pain specialists, and other relevant specialists for comprehensive management (Evidence: Expert opinion) 3.
Prenatal and Newborn Screening: Implement universal newborn screening programs to identify affected infants early (Evidence: Moderate) 1.
Annual Transcranial Doppler: For pediatric patients to assess stroke risk and guide prophylactic interventions (Evidence: Strong) 3.
Regular Growth and Development Assessments: Especially important in pediatric patients to address growth retardation (Evidence: Moderate) 3.
Pregnancy Management: Close collaboration between hematology and obstetric teams to manage complications during pregnancy (Evidence: Expert opinion) 3.References
1 Shah U, Bhattarai R, Al Salami H, Blanchard C, Johnson SK. Fabrication and Characterization of Kafirin Microparticles Made Using Ionic Gelation Vibrational Jet Flow Technology: Influence of Processing Parameters on Physicochemical Properties. Journal of food science 2026. link
2 Wang M, Liu S, Wang Z, Li B, Li L, Wang Z et al.. Accurate and online quantification of viable Rhodobacter sphaeroides cells using a flow cytometry-dielectric spectroscopy (FCM-DS) method. Talanta 2022. link
3 Xu AS, Ohba Y, Vida L, Labotka RJ, London RE. Aspirin acetylation of betaLys-82 of human hemoglobin. NMR study of acetylated hemoglobin Tsurumai. Biochemical pharmacology 2000. link00419-6)
4 Hundley DS, Vertrees RA, Brownstein L, Clancy M, Garwood AP, DelRossi AJ. Determination and comparison of heat exchange efficiency of four commercially available blood cardioplegia sets. Perfusion 1994. link
5 Wieder ED, Hang H, Fox MH. Measurement of intracellular pH using flow cytometry with carboxy-SNARF-1. Cytometry 1993. link